This table will no longer be updated after 5/30/2024 given the end of the 2023-2024 viral respiratory vaccine season.

This table shows the cumulative number and percentage of CT residents who have received an updated COVID-19 vaccine during the 2023-2024 viral respiratory season by age group (current age).
CDC recommends that people get at least one dose of this vaccine to protect against serious illness, whether or not they have had a COVID-19 vaccination before. Children and people with moderate to severe immunosuppression might be recommended more than one dose. For more information on COVID-19 vaccination recommendations, click here.
• Data are reported weekly on Thursday and include doses administered to Saturday of the previous week (Sunday – Saturday). All data in this report are preliminary. Data from the previous week may be changed because of delays in reporting, deduplication, or correction of errors.
• These analyses are based on data reported to CT WiZ which is the immunization information system for CT. CT providers are required by law to report all doses of vaccine administered. CT WiZ also receives records on CT residents vaccinated in other jurisdictions and by federal entities which share data with CT Wiz electronically. Electronic data exchange is being added jurisdiction-by-jurisdiction. Currently, this includes Rhode Island and New York City but not Massachusetts and New York State. Therefore, doses administered to CT residents in neighboring towns in Massachusetts and New York State will not be included. A full list of the jurisdiction with which CT has established electronic data exchange can be seen at the bottom of this page (https://portal.ct.gov/immunization/Knowledge-Base/Articles/Vaccine-Providers/CT-WiZ-for-Vaccine-Providers-and-Training/Query-and-Response-functionality-in-CT-WiZ?language=en_US)
• Population size estimates used to calculate cumulative percentages are based on 2020 DPH provisional census estimates*.
• People are included if they have an active jurisdictional status in CT WiZ at the time weekly data are pulled. This excludes people who live out of state, are deceased and a small percentage who have opted out of CT WiZ.
* DPH Provisional State and County Characteristics Estimates April 1, 2020. Hayes L, Abdellatif E, Jiang Y, Backus K (2022) Connecticut DPH Provisional April 1, 2020, State Population Estimates by 18 age groups, sex, and 6 combined race and ethnicity groups. Connecticut Department of Public Health, Health Statistics & Surveillance, SAR, Hartford, CT.

Note: As of 1/22/25, this dataset is no longer updated. This dataset reports the number of people vaccinated by New York providers with at least one dose and with a complete COVID-19 vaccination series overall since December 14, 2020. Currently, three COVID-19 vaccines have been authorized for emergency use by the FDA and approved by New York State's independent Clinical Advisory Task Force: one that was developed by Pfizer and BioNTech, a second that was developed by Moderna and a third that was developed by Janssen/Johnson & Johnson. New York providers include hospitals, mass vaccination sites operated by the State or local governments, pharmacies, and other providers registered with the state to serve as points of distribution. This dataset is created by the New York State Department of Health from data reported to the New York State Immunization Information System (NYSIIS) and the New York City Citywide Immunization Registry (NYC CIR).

NYSIIS and CIR are confidential, secure, web-based systems that collect and maintain immunization information in one consolidated record for persons of all ages in NYS governed by Public Health Law 2168. Health care providers are required, by law, to enter all vaccines administered to children up to age 19. Immunizations administered to adults 19 and older may be reported with consent. New York State Department of Health requires all New York State vaccination providers to report all COVID-19 vaccination administration data to NYSIIS and NYC CIR within 24 hours of administration.

Vaccination data by age is based on address data reported to NYSIIS and NYC CIR by the providers administering vaccines. Age is calculated by subtracting the dob from the date of vaccination. Note that COVID-19 vaccine availability greatly expanded for the different age groups over the period of time this dataset covers. This data does not include vaccine administered through Federal entities or performed outside of New York State to New York residents. NYSIIS and CIR data is used for age group statistics. This dataset is updated weekly.

Note: As of November 10, 2023, this dataset has been archived. For the current version of this data, please visit: https://health.data.ny.gov/d/gikn-znjh

This dataset reports daily on the number of people vaccinated by New York providers with at least one dose and with a complete COVID-19 vaccination series overall since December 14, 2020. New York providers include hospitals, mass vaccination sites operated by the State or local governments, pharmacies, and other providers registered with the State to serve as points of distribution.

This dataset is created by the New York State Department of Health from data reported to the New York State Immunization Information System (NYSIIS) and the New York City Citywide Immunization Registry (NYC CIR). County-level vaccination data is based on data reported to NYSIIS and NYC CIR by the providers administering vaccines. Residency is self-reported by the individual being vaccinated. This data does not include vaccine administered through Federal entities or performed outside of New York State to New York residents. NYSIIS and CIR data is used for county-level statistics. New York State Department of Health requires all New York State vaccination providers to report all COVID-19 vaccination administration data to NYSIIS and NYC CIR within 24 hours of administration.

Novel Vaccine Delivery Systems Market Outlook

In 2023, the global market size for novel vaccine delivery systems was approximately USD 3.5 billion and is projected to reach USD 6.8 billion by 2032, registering a CAGR of 7.5% during the forecast period. This growth is primarily driven by technological advancements in vaccine delivery mechanisms, coupled with the increasing prevalence of infectious diseases and cancer. The noteworthy increase in vaccination rates worldwide, along with supportive government initiatives, are also fueling the market expansion.

One of the significant growth factors for the novel vaccine delivery systems market is the technological innovation in drug delivery methods. Traditional syringe-based vaccination methods often encounter issues such as needle phobia and the risk of contamination. Modern delivery systems, such as microneedles and liposomes, offer minimally invasive, more precise, and safer alternatives for administering vaccines. These technologies are being increasingly adopted due to their ability to enhance immune responses and reduce side effects, offering a significant improvement over traditional methods.

The global burden of infectious diseases remains a crucial driver for this market. With the rise in global travel and urbanization, the spread of infectious diseases has become more rampant, necessitating effective vaccination strategies. The COVID-19 pandemic underscored the importance of rapid and efficient vaccine delivery systems, accelerating research and development in this field. Emerging pathogens and the re-emergence of diseases like measles have further emphasized the need for better vaccine delivery technologies.

Another vital growth factor is the increasing incidence of cancer and the development of cancer vaccines. Cancer vaccines, which aim to prevent or treat cancer by strengthening the body's natural defenses, require specialized delivery mechanisms to be effective. Novel delivery systems such as nanoparticles and viral vectors have shown promise in enhancing the efficacy of these vaccines, providing a significant impetus for market growth. The rising investment in cancer vaccine research by both public and private sectors is expected to sustain this growth trajectory.

Noninvasive Vaccination is emerging as a transformative approach in the field of vaccine delivery. This method aims to administer vaccines without the use of needles, addressing common issues such as needle phobia and the risk of needle-stick injuries. Technologies like microneedles, transdermal patches, and nasal sprays are at the forefront of this innovation, offering a painless and convenient alternative for vaccine administration. Noninvasive methods not only enhance patient compliance but also facilitate mass immunization efforts, particularly in resource-limited settings. The development of these technologies is driven by the need for safer, more efficient vaccine delivery systems that can be easily deployed during pandemics or in remote areas. As research progresses, noninvasive vaccination is expected to play a crucial role in expanding global vaccination coverage and improving public health outcomes.

Regional outlooks indicate that North America and Europe are currently the largest markets for novel vaccine delivery systems, driven by high healthcare expenditure, robust infrastructure, and significant R&D activities. However, the Asia Pacific region is projected to witness the highest growth rate during the forecast period. This growth is attributed to increasing government initiatives for immunization, rising healthcare awareness, and expanding biopharmaceutical industries in countries like China and India. Latin America and the Middle East & Africa are also anticipated to experience growth due to improving healthcare infrastructure and increasing vaccination programs.

Delivery Method Analysis

Microneedles are an innovative delivery method gaining significant traction in the market. These tiny needles, often no longer than a few micrometers, can painlessly penetrate the skin to deliver vaccines directly into the dermis or epidermis. This method reduces the risk of needle-stick injuries and improves patient compliance, especially in pediatric and geriatric populations. Recent advancements in microneedle technology have led to the development of dissolvable and biodegradable microneedles, which eliminate the need for medical waste disposal, making them an eco-friendly alternative.

In these analyses, individuals vaccinated before the identified time duration considered unvaccinatedModel A: Adjusted for age, gender, place of residence;**Model B: Adjusted for Model A variables plus income, comorbidity, A(H1N1)pdm09 priority group, receiving the 2009/10 seasonal influenza vaccine, receiving a pneumococcal vaccine, immunosuppressed, pregnancy, ≥20 physician encounters in the last 5 years, ≥1 hospital admission in the last 5 years; use of antiviral prophylaxis and diagnosis of chronic renal failure.† Exact numbers between 1–5 are not reported as required by the data custodian to protect patient confidentiality.Estimates of the effectiveness (VE) of pandemic, seasonal influenza and pneumococcal vaccine against hospitalization with laboratory-confirmed influenza*.

Noninvasive Delivery Vaccine Market Outlook

The global noninvasive delivery vaccine market size was valued at $3.5 billion in 2023 and is projected to reach $12.1 billion by 2032, growing at a compound annual growth rate (CAGR) of 15.2% during the forecast period. The significant growth of this market is primarily driven by advancements in biotechnology, increasing public awareness about vaccination benefits, and the pressing need for mass immunization against various diseases.

One of the primary growth factors for the noninvasive delivery vaccine market is the growing demand for pain-free and needle-free vaccination methods. Traditional injection-based vaccines often face resistance due to the discomfort and fear associated with needles, particularly among children and those with needle phobia. Noninvasive delivery methods, such as nasal sprays and transdermal patches, offer a more comfortable and user-friendly alternative, enhancing patient compliance and vaccination coverage.

Another crucial factor contributing to market growth is the rapid advancements in vaccine technology. Innovations in biotechnology have led to the development of more stable and effective noninvasive vaccines, which can be easily administered without the need for trained healthcare professionals. This accessibility is particularly beneficial in low-resource settings and rural areas where healthcare infrastructure is limited. Additionally, noninvasive vaccines often do not require cold chain storage, making them more suitable for distribution in remote regions.

Moreover, the ongoing COVID-19 pandemic has underscored the importance of mass vaccination and the need for efficient vaccine delivery systems. Governments and healthcare organizations worldwide have been actively investing in the research and development of noninvasive vaccine delivery methods to ensure swift and widespread vaccination. Public-private partnerships and increased funding for vaccine research are expected to further accelerate the growth of the noninvasive delivery vaccine market.

Regionally, North America currently dominates the noninvasive delivery vaccine market due to the presence of leading biotechnology companies and advanced healthcare infrastructure. However, the Asia Pacific region is anticipated to witness the highest growth rate during the forecast period. The increasing prevalence of infectious diseases, rising healthcare expenditure, and growing awareness about vaccination benefits in countries like China and India are driving the market expansion in this region.

In addition to the advancements in vaccine technology, the packaging and distribution of vaccines play a crucial role in ensuring their efficacy and accessibility. IsOthersmal Boxes for Vaccines have emerged as a significant innovation in this regard. These boxes are designed to maintain the required temperature for vaccines during transportation, ensuring that they remain effective until they reach their destination. The use of IsOthersmal Boxes is particularly important in regions with extreme temperatures or limited access to refrigeration facilities. By providing a reliable solution for vaccine storage and transport, these boxes help enhance the overall efficiency of vaccination programs, especially in remote and underserved areas.

Delivery Method Analysis

The noninvasive delivery vaccine market is segmented by various delivery methods, including nasal sprays, oral vaccines, transdermal patches, jet injectors, and others. Among these, nasal sprays are gaining significant traction due to their ease of use and rapid absorption through the nasal mucosa. Nasal vaccines are particularly effective in inducing local immune responses, making them suitable for respiratory infections such as influenza and COVID-19. The simplicity of nasal spray administration also makes it a preferred choice for mass vaccination campaigns.

Oral vaccines are another prominent segment in the noninvasive delivery method. These vaccines are administered through the oral route, typically in the form of liquid drops or capsules. Oral vaccines have the advantage of being easy to administer and are particularly effective in inducing mucosal immunity in the gastrointestinal tract. This makes them ideal for combating enteric diseases such as cholera and rotavirus. Additionally, oral vaccines can be easily administered to children, enhancing vaccination coverage in pediatric populations.

Vaccine Administration Market Outlook

The global vaccine administration market size was estimated at USD 5.2 billion in 2023 and is projected to reach USD 11.4 billion by 2032, with a compound annual growth rate (CAGR) of 9.1%. This impressive growth is driven by several factors, including advancements in vaccine delivery technologies, increased vaccination efforts worldwide, and rising awareness about the importance of immunizations.

One of the primary growth factors for the vaccine administration market is the ongoing global effort to eradicate infectious diseases through widespread immunization programs. Governments and health organizations worldwide have been emphasizing the importance of vaccination, leading to increased vaccine coverage and administration rates. The COVID-19 pandemic has further accentuated the critical role of vaccinations, thereby boosting the market growth. The introduction of novel vaccines and booster doses has necessitated advancements in vaccine delivery systems, contributing to the overall market expansion.

Technological advancements in vaccine administration devices have significantly spurred market growth. Innovations such as needle-free jet injectors, intranasal devices, and improved syringe designs have enhanced the efficiency, safety, and patient compliance of vaccine administration. These advancements reduce the risk of needle-stick injuries, minimize vaccine wastage, and improve the overall vaccination experience. Moreover, the increasing adoption of smart syringes with integrated tracking and safety features aligns with global efforts to ensure vaccine integrity and monitoring.

The collaboration between public and private sectors has been a significant driver in the vaccine administration market. Public health initiatives, partnerships with pharmaceutical companies, and funding from international organizations have bolstered the production, distribution, and administration of vaccines. Financial support for vaccine research and development has accelerated the introduction of new vaccines, creating a robust pipeline for future market growth. Additionally, government policies and reimbursement frameworks have made vaccines more accessible, particularly in low- and middle-income countries, further propelling market expansion.

The regional outlook for vaccine administration is highly promising, with considerable growth anticipated across various geographies. North America, driven by high healthcare expenditure and robust immunization programs, holds a significant market share. The Asia Pacific region is expected to showcase the highest growth rate due to rising healthcare investments, large population base, and increasing awareness regarding vaccine-preventable diseases. Europe also presents substantial growth opportunities, supported by strong government initiatives and advanced healthcare infrastructure. Latin America and the Middle East & Africa, though currently smaller markets, are poised for notable growth due to improving healthcare access and ongoing immunization campaigns.

Product Type Analysis

The vaccine administration market can be segmented by product type into syringes, jet injectors, intranasal devices, and others. Syringes remain the most widely used device for vaccine administration due to their cost-effectiveness, simplicity, and widespread availability. The advancements in syringe technology, such as auto-disable and prefilled syringes, have enhanced safety, reduced contamination risks, and minimized vaccine wastage. The dominance of syringes in the market is further reinforced by their extensive use in routine immunization programs and emergency vaccination drives globally.

Jet injectors represent an innovative leap in the vaccine delivery landscape, offering needle-free administration that improves patient compliance and reduces needle-associated risks. These devices use high-pressure streams to deliver vaccines through the skin, eliminating the need for needles and enhancing the overall vaccination experience. Jet injectors are particularly beneficial in mass immunization settings and for individuals with needle phobia. Their growing popularity is driven by ongoing technological advancements and increasing acceptance among healthcare providers and patients alike.

Intranasal devices have emerged as a promising alternative for vaccine administration, especially for respiratory infections. These devices deliver vaccines directly to the nasal mucosa, eliciting both systemic and mucosal immunity. The ease of administration, coupled with the potential for self-administ

The following dashboards provide data on contagious respiratory viruses, including acute respiratory diseases, COVID-19, influenza (flu), and respiratory syncytial virus (RSV) in Massachusetts. The data presented here can help track trends in respiratory disease and vaccination activity across Massachusetts.

Mass vaccination clinics efficiently vaccinate large numbers of people. The CARD system (Comfort, Ask, Relax, Distract) is a vaccination delivery framework that can improve the experiences of vaccine recipients and providers. This two-stage hybrid effectiveness-implementation study implemented and sustained CARD in university-based vaccination clinics involving pharmacy student vaccinators. Stage 1 was a before-and-after study conducted across four COVID-19 vaccination clinics in November-December, 2022. Stage 2 was a single cohort study whereby CARD was sustained across four COVID-19/influenza vaccination clinics in November, 2023. In both stages, vaccine recipients rated experiences relative to last vaccination (primary outcome) and symptoms (pain, fear, dizziness) using surveys. Pharmacy student vaccinators completed attitudes and behaviors surveys; a subsample participated in focus groups. In Stage 1, more vaccine recipients in the after period (vs. before) reported a better vaccination experience relative to their last vaccination (64.0% vs 33.6%; p 

Vaccine Delivery Devices Market Outlook

According to our latest research, the global vaccine delivery devices market size reached USD 6.3 billion in 2024. The market is witnessing robust expansion and is projected to grow at a CAGR of 7.1% from 2025 to 2033. By the end of this forecast period, the market is expected to attain a value of USD 11.8 billion. This growth is primarily driven by the increasing prevalence of infectious diseases, advancements in vaccine technology, and the rising demand for efficient and safe vaccine administration methods worldwide.

One of the key growth factors fueling the vaccine delivery devices market is the escalating incidence of infectious diseases such as influenza, hepatitis, and, more recently, COVID-19. The global healthcare system has witnessed a significant uptick in immunization programs, both in developed and emerging economies, which has led to a surge in demand for innovative vaccine delivery solutions. Governments and international organizations are heavily investing in vaccination campaigns, which, in turn, is creating a substantial need for reliable and user-friendly vaccine delivery devices. Additionally, the growing awareness among populations regarding the benefits of vaccination and the availability of multiple vaccine types has further augmented the market’s growth trajectory.

Technological advancements are another crucial factor propelling the vaccine delivery devices market. The development of novel delivery technologies, such as microneedle patches and jet injectors, is revolutionizing the way vaccines are administered. These innovations are designed to enhance patient compliance, reduce pain and anxiety associated with traditional needle-based delivery, and minimize the risk of needle-stick injuries. Moreover, such devices are particularly valuable in mass immunization settings, where speed, safety, and ease of use are paramount. The integration of smart technologies and digital tracking systems with vaccine delivery devices is also enabling better monitoring and management of vaccination programs, thereby boosting market growth.

The vaccine delivery devices market is also benefiting from the increasing focus on self-administration and home-based care. The COVID-19 pandemic has accelerated the adoption of remote healthcare solutions, including self-administered vaccines and devices suitable for home use. This trend is supported by the growing elderly population, the rising prevalence of chronic diseases, and the need for flexible healthcare delivery models. As a result, manufacturers are developing user-friendly devices that can be safely used outside traditional healthcare settings, thereby expanding the market’s reach and accessibility.

From a regional perspective, North America continues to dominate the vaccine delivery devices market, accounting for the largest share in 2024, followed closely by Europe and Asia Pacific. The region’s leadership is attributed to advanced healthcare infrastructure, high vaccination coverage, and strong government support for immunization programs. However, Asia Pacific is emerging as the fastest-growing market, driven by its large population base, increasing healthcare expenditure, and growing awareness about immunization. Latin America and the Middle East & Africa are also witnessing steady growth, supported by international vaccination initiatives and improving healthcare access.

Product Type Analysis

The vaccine delivery devices market, when segmented by product type, reveals a diverse range of technologies, each catering to specific needs and preferences in immunization. Syringes remain the most widely used devices due to their proven efficacy, ease of use, and cost-effectiveness. They are the cornerstone of most immunization programs globally, especially in large-scale public health initiatives. The demand for syringes is further bolstered by the ongoing need for booster shots and routine vaccinations. However, concerns regarding needle-stick injuries and the risk of cross-contamination are prompting healthcare providers to seek alternative delivery methods.

Jet injectors are gaining significant traction as a needle-free alternative, particularly in settings where rapid mass vaccination is required. These devices utilize high-pressure streams to deliver vaccines intradermally, subcutaneously, or intramuscularly, thereby

Norovirus Vaccine Market Outlook

According to our latest research, the global Norovirus Vaccine market size reached USD 1.18 billion in 2024, reflecting robust development in vaccine research and public health initiatives. The market is expected to grow at a CAGR of 7.3% from 2025 to 2033, reaching an estimated value of USD 2.22 billion by 2033. This sustained growth is primarily driven by increased awareness of norovirus infection risks, advancements in vaccine technology, and expanding immunization programs worldwide.

A significant growth factor for the Norovirus Vaccine market is the rising global incidence of norovirus outbreaks, particularly in healthcare and community settings. Norovirus is a leading cause of acute gastroenteritis, responsible for millions of cases annually, especially among vulnerable populations such as children, the elderly, and immunocompromised individuals. The burden on healthcare systems and the associated economic costs have compelled governments and health organizations to prioritize vaccine development and deployment. As a result, funding for research and clinical trials has surged, enabling pharmaceutical companies to accelerate the introduction of novel vaccine candidates into the market.

Another major driver is the advancement in vaccine platforms, including recombinant and inactivated vaccines. These technologies have improved the safety profile and efficacy of norovirus vaccines, making them more appealing for regulatory approval and mass immunization campaigns. The integration of novel adjuvants and delivery systems has further enhanced vaccine immunogenicity, resulting in longer-lasting protection and fewer adverse events. The robust pipeline of vaccine candidates, supported by strategic collaborations between biotechnology firms, academic institutions, and government agencies, is expected to propel market growth over the forecast period.

Furthermore, the expansion of immunization programs targeting norovirus in both developed and emerging economies is contributing substantially to market expansion. Increased public awareness about the severe consequences of norovirus infections, particularly in pediatric and geriatric populations, has led to higher vaccine uptake rates. Health authorities are increasingly incorporating norovirus vaccination into routine immunization schedules, especially in countries with high disease prevalence. The growing emphasis on preventive healthcare and the implementation of supportive reimbursement policies are also facilitating greater access to norovirus vaccines, thereby supporting sustained market growth.

From a regional perspective, North America and Europe currently dominate the Norovirus Vaccine market owing to their advanced healthcare infrastructure, high disease surveillance capabilities, and significant investments in vaccine research and development. However, the Asia Pacific region is anticipated to witness the fastest growth during the forecast period, driven by rising healthcare expenditures, increasing awareness of norovirus infections, and expanding immunization coverage. Latin America and the Middle East & Africa are also emerging as important markets, supported by international initiatives to improve vaccine accessibility and disease prevention measures.

Vaccine Type Analysis

The Norovirus Vaccine market, segmented by vaccine type, includes Live Attenuated Vaccines, Inactivated Vaccines, Recombinant Vaccines, and Others. Among these, recombinant vaccines have gained significant traction due to their enhanced safety profiles and ability to induce strong immune responses. These vaccines utilize advanced genetic engineering techniques to create virus-like particles that mimic norovirus antigens, thereby eliciting robust immunity without the risk of causing disease. The ongoing research into optimizing recombinant vaccine formulations has resulted in several candidates progressing through late-stage clinical trials, positioning this segment as a key driver of market growth.&

What is the FluPRINT database?

The FluPRINT represents fully integrated and normalized immunology measurements from eight clinical studies taken from 740 individuals undergoing influenza vaccination with inactivated or live attenuated seasonal influenza vaccines from 2007 to 2015 at the Stanford Human Immune Monitoring Center.

The FluPRINT dataset contains information on more than 3,000 parameters measured using mass cytometry, flow cytometry, phosphorylation-specific cytometry, multiplex cytokine assays, clinical lab tests (hormones and complete blood count), serological profiling and virological tests. In the dataset, vaccine protection is measured using a hemagglutination inhibition (HAI) assay, and following FDA guidelines individuals are marked as high or low responders depending on the HAI antibody titers after vaccination.

Want to know more?

To understand how the FluPRINT dataset was generated and validated, and how to use it, please refer to our open-access paper published in Scientific Data journal:

Tomic, A., Tomic, I., Dekker, C.L. et al. The FluPRINT dataset, a multidimensional analysis of the influenza vaccine imprint on the immune system. Sci Data 6, 214 (2019). https://doi.org/10.1038/s41597-019-0213-4

For additional exploration, please check out the project’s website: www.fluprint.com, where you can also explore the FluPRINT dataset on the following link: https://fluprint.com/#/database-access.

If you want to host your own FluPRINT database, please follow our instructions provided on the Github repository: https://github.com/LogIN-/fluprint.

How to use FluPRINT?

Here, you can download the entire FluPRINT database export as an SQL file, or as a CSV file. Additionally, we included the file with the SQL query to obtain those files.

Files are provided in two formats: zip and 7zip (7z). 7zip is a free and open-source file archiver available for download here: https://www.7-zip.org.

In the FluPRINT database, there are 4 tables: donor, donor_visits, experimental_data, and medical_history.
The exact description of each table is available in the FluPRINT paper.

Briefly, in the table donor, each row represents an individual with information about the clinical study in which an individual was enrolled (study ID and study internal ID), gender, and race. The second table, named donor_visits describes information about the donor’s age, cytomegalovirus (CMV) and Epstein-Barr virus (EBV) status, Body Mass Index (BMI), and vaccine received on each clinical visit. Information about vaccine outcome is available as geometric mean titers (geo_mean), the difference in the geometric mean titers before and after vaccination (delta_geo_mean), and the difference for each vaccine strain (delta_single). In the last field, each individual is classified as a high and low responder (vaccine_resp). On each visit, samples were analyzed and information about which assays were performed (assay field) and value of the measured analytes (units and data) are stored in the experimental_data table. Finally, the medical_history table describes information connected with each clinical visit about the usage of statins (statin_use) and if influenza vaccine was received in the past (influenza vaccine history), if yes, how many times (total_vaccines_received). Also, we provide information on which type of influenza vaccine was received in the previous years (1 to 5 years prior to enrolment in the clinical study). Lastly, information about influenza infection history and influenza-related hospitalization is provided.

How to cite FluPRINT?

If you use FluPRINT in an academic publication, please use the following citation:

Tomic, A., Tomic, I., Dekker, C.L. et al. The FluPRINT dataset, a multidimensional analysis of the influenza vaccine imprint on the immune system. Sci Data 6, 214 (2019). https://doi.org/10.1038/s41597-019-0213-4

Contact Information

If you are interested to find out more about the FluPRINT, or if you experience any problems with downloading files, please contact us at info@adrianatomic.com.

Oral Polio Vaccines (OPV) Market Outlook

The global Oral Polio Vaccines (OPV) market size is projected to grow significantly from 2023 to 2032, with a compound annual growth rate (CAGR) of approximately 5.2%. The market size in 2023 stands at $1.45 billion and is forecasted to reach $2.34 billion by 2032, driven by a combination of factors including increasing government initiatives, rising awareness about immunization, and technological advancements in vaccine development.

One of the key growth factors driving the Oral Polio Vaccines market is the increased focus on eradicating poliomyelitis globally. Governments and non-governmental organizations are heavily investing in immunization programs, which are aimed not only at broad-spectrum disease prevention but also at addressing the last pockets of polio presence in the world. This heightened focus has accelerated the adoption of OPV, particularly in regions that have seen outbreaks in recent years. Enhanced surveillance systems and global partnerships, such as those led by the World Health Organization (WHO) and the Global Polio Eradication Initiative (GPEI), play a pivotal role in this growth.

Technological advancements also contribute significantly to the market's expansion. Modern OPV formulations offer more effective immunization with fewer doses, thereby improving compliance and coverage rates. Innovations in cold chain logistics ensure that vaccines are stored and transported under optimal conditions, reducing wastage and enhancing the efficiency of immunization programs. Moreover, research and development efforts focused on combining OPV with other vaccines could further fuel market growth by simplifying immunization schedules and improving overall public health outcomes.

Another factor propelling the market growth is increasing public awareness about the importance of vaccination. Education campaigns led by governments, healthcare providers, and international health organizations have effectively communicated the benefits of OPV, leading to higher uptake rates. Social media platforms and digital health information systems are also playing a crucial role in spreading awareness and countering vaccine misinformation, thus fostering a more informed and health-conscious population.

The development and deployment of the Poliovirus Vaccine have been pivotal in the global fight against polio. This vaccine, which includes both oral and inactivated forms, has drastically reduced the incidence of polio worldwide. The oral poliovirus vaccine (OPV) has been particularly effective in mass immunization campaigns due to its ease of administration and ability to induce strong intestinal immunity, which is crucial for interrupting person-to-person transmission of the virus. The continued innovation in vaccine formulations, including the development of novel poliovirus vaccines, ensures that immunization programs can adapt to emerging challenges, such as vaccine-derived poliovirus outbreaks. These efforts are supported by extensive research and collaborations among international health organizations, governments, and pharmaceutical companies, all working towards the ultimate goal of a polio-free world.

Regionally, the Asia Pacific region is poised for significant growth in the OPV market owing to its large population base and ongoing government initiatives aimed at eradicating polio. Countries like India and Pakistan are at the forefront of these efforts, given their historical burden of polio cases. North America and Europe, with their well-established healthcare infrastructures, are expected to maintain stable market growth. Meanwhile, Africa, still facing challenges in healthcare infrastructure, is projected to see moderate growth, driven by international funding and localized immunization campaigns.

Type Analysis

The OPV market can be segmented by type into Monovalent OPV, Bivalent OPV, and Trivalent OPV. Monovalent OPV (mOPV) targets a single strain of the poliovirus and is often used in outbreak settings or in regions where one type of poliovirus predominates. The specificity of mOPV makes it a vital tool in targeted immunization campaigns aimed at quickly containing outbreaks of a particular poliovirus strain. Its use has been pivotal in recent efforts to halt the spread of polio in endemic regions, particularly where type 2 poliovirus is a concern.

Bivalent OPV (bOPV) targets two strains of the poliovirus and has been instrumental in broadening th

Vaccine Delivery Devices Market Outlook

According to our latest research, the global vaccine delivery devices market size stood at USD 6.4 billion in 2024, reflecting robust demand and technological advancements across the healthcare sector. The market is poised to expand at a CAGR of 7.9% during the forecast period, reaching a projected value of USD 12.8 billion by 2033. This growth trajectory is fueled by increasing immunization initiatives, rising prevalence of infectious diseases, and continuous innovation in vaccine administration technologies. The surge in global vaccination campaigns and the development of novel vaccine formulations are further accelerating the adoption of advanced delivery devices, making this market a focal point for healthcare investments and public health strategies.

One of the primary growth drivers for the vaccine delivery devices market is the escalating incidence of infectious diseases worldwide, including both emerging and re-emerging pathogens. The COVID-19 pandemic has notably underscored the critical need for efficient and scalable vaccine delivery systems, prompting governments and health organizations to invest heavily in immunization infrastructure. Additionally, the growing awareness regarding the importance of vaccination, coupled with expanding immunization coverage among pediatric and geriatric populations, is propelling demand for diverse vaccine delivery devices. Technological innovations, such as microneedle patches and jet injectors, are further enhancing patient compliance and offering pain-free alternatives to traditional syringes, thereby broadening the market’s appeal.

Another significant factor contributing to market growth is the continuous evolution of vaccine formulations that require specialized delivery mechanisms. The development of mRNA vaccines, recombinant vaccines, and other next-generation immunizations necessitates precision in administration, often facilitated by advanced devices like microneedle patches and oral delivery systems. Moreover, the increasing prevalence of chronic diseases and the rising focus on preventive healthcare are driving demand for mass immunization programs, particularly in developing economies. This, in turn, is encouraging manufacturers to innovate and diversify their product portfolios to meet the varying needs of healthcare providers and patients across different age groups and geographies.

The expanding role of public-private partnerships and global health initiatives is also playing a pivotal role in shaping the vaccine delivery devices market. Organizations such as the World Health Organization (WHO), GAVI, and UNICEF are collaborating with governments and private sector players to enhance vaccine accessibility and affordability in low- and middle-income countries. These efforts are not only strengthening immunization infrastructure but also fostering the adoption of novel delivery technologies. Furthermore, the integration of digital health solutions and supply chain optimization is streamlining vaccine distribution and administration, thereby supporting the market’s sustained growth and resilience against future health crises.

From a regional perspective, North America currently dominates the vaccine delivery devices market, accounting for the largest share owing to its advanced healthcare infrastructure, high vaccination rates, and strong presence of leading market players. Europe follows closely, driven by favorable government policies and increasing investments in immunization programs. However, the Asia Pacific region is anticipated to witness the fastest growth during the forecast period, propelled by rising healthcare expenditure, growing population, and heightened awareness about vaccine-preventable diseases. Latin America and the Middle East & Africa are also emerging as promising markets, supported by international aid programs and efforts to improve healthcare delivery systems.

Product Type Analysis

The vaccine delivery devices market is segmented by product type int

Oral Vaccine For Human Market Outlook

As of 2023, the global market size for oral vaccines for humans is valued at approximately $4.5 billion and is projected to reach around $8.7 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 7.2%. This growth is driven by a myriad of factors including advancements in vaccine technology and increasing governmental support for immunization programs worldwide.

One of the primary growth factors for the oral vaccine market is the ease and convenience of administration compared to injectable vaccines. Oral vaccines eliminate the need for needles, reducing the risk of needle-stick injuries and lowering the burden on healthcare systems in terms of trained personnel and facilities. This is particularly beneficial in low-resource settings where healthcare infrastructure may be lacking. Additionally, oral vaccines generally do not require reconstitution or cold chain storage, making them more suitable for mass immunization campaigns in remote or underserved areas.

Another significant growth driver is the increasing prevalence of infectious diseases that can be effectively targeted by oral vaccines. Diseases such as cholera, typhoid, and rotavirus-related illnesses continue to affect millions of people annually, particularly in developing countries. The rising incidence of these diseases has led to greater demand for efficient and accessible vaccination solutions. Governments and international organizations are increasingly prioritizing vaccination programs, thereby driving the demand for oral vaccines.

Technological advancements and research in vaccine development are also crucial contributors to market growth. Modern biotechnological techniques have enabled the development of more effective and safer oral vaccines. Innovations such as DNA vaccines and subunit vaccines are expected to offer robust protection against a variety of pathogens. These advancements not only enhance the efficacy and safety profiles of vaccines but also reduce the time and cost involved in their production.

Regionally, Asia Pacific is expected to witness substantial growth in the oral vaccine market over the forecast period. This can be attributed to the large population base, increasing government initiatives for vaccination, and the prevalence of infectious diseases in the region. Additionally, countries like India and China are becoming significant manufacturing hubs for vaccines, further propelling market growth. North America and Europe are also expected to maintain steady growth due to high healthcare expenditure and ongoing research and development activities in these regions.

Vaccine Type Analysis

The oral vaccine market is segmented by vaccine type into Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, DNA Vaccines, and Others. Live attenuated vaccines are currently the most dominant segment due to their high efficacy and long-lasting immunity. These vaccines are created by weakening the virus or bacteria so that it cannot cause disease but still elicits a strong immune response. They are particularly effective for diseases like rotavirus and typhoid, offering robust protection with minimal doses.

Inactivated vaccines are also a significant segment in the oral vaccine market. Unlike live attenuated vaccines, inactivated vaccines contain pathogens that have been killed or inactivated. While they are often considered safer for immunocompromised individuals, they generally require multiple doses to achieve the same level of immunity. Recent advancements in this category have focused on enhancing their immunogenicity and stability, making them more efficient and easier to distribute.

Subunit vaccines represent another promising segment. These vaccines contain only the essential antigens that best stimulate the immune system, rather than the whole pathogen. This makes subunit vaccines safer, with fewer side effects compared to live attenuated or inactivated vaccines. Recent research has been directed towards improving the delivery systems of these vaccines to increase their efficacy. For instance, nanoparticle-based delivery systems are being explored to enhance immune response.

DNA vaccines are an emerging and innovative category within the oral vaccine market. These vaccines use genetic material from the pathogen to induce an immune response. They offer several advantages, including the ability to be rapidly designed and produced. DNA vaccines are stable at room temperature, eliminating the need for cold chain logistics, which is particular

DNA Vaccine Electroporation Patch Market Outlook

As per our latest research, the global DNA Vaccine Electroporation Patch market size reached USD 412 million in 2024, demonstrating robust momentum with a compound annual growth rate (CAGR) of 18.7% from 2025 to 2033. By the end of 2033, the market is forecasted to achieve a valuation of USD 2.1 billion, fueled by rising investments in biotechnology, increasing prevalence of infectious diseases, and the accelerating adoption of advanced drug delivery systems. The significant growth in this sector is primarily attributed to the expanding pipeline of DNA vaccines, the need for efficient and minimally invasive vaccine delivery solutions, and favorable regulatory support for next-generation immunization technologies.

A major growth driver for the DNA Vaccine Electroporation Patch market is the rising global burden of infectious diseases, which has intensified the demand for rapid, safe, and effective vaccine delivery methods. Traditional needle-based vaccination methods pose challenges such as pain, needle phobia, and the risk of infection transmission. Electroporation patches offer a minimally invasive alternative, enhancing DNA vaccine uptake by temporarily permeabilizing cell membranes, thereby improving immunogenicity. The COVID-19 pandemic further underscored the importance of innovative vaccine delivery platforms, prompting governments and health organizations to invest heavily in research and development. This has led to a surge in clinical trials and regulatory approvals for DNA vaccines utilizing electroporation technology, directly contributing to the rapid expansion of the market.

Technological advancements in the design and functionality of electroporation patches are also propelling market growth. The integration of wearable, disposable, and reusable patch formats has significantly improved patient compliance, ease of administration, and cost-effectiveness. Wearable electroporation patches, in particular, allow for self-administration and continuous monitoring, reducing the need for frequent hospital visits. These innovations not only streamline vaccine deployment during mass immunization campaigns but also open new avenues for personalized medicine and home healthcare. Furthermore, collaborations between pharmaceutical companies, biotech startups, and academic institutions are accelerating the commercialization of novel patch-based delivery systems, thereby broadening the application scope of DNA vaccine electroporation patches beyond infectious diseases to include cancer immunotherapy and veterinary medicine.

Another critical factor driving the DNA Vaccine Electroporation Patch market is the favorable regulatory environment and increased funding initiatives from governmental and non-governmental organizations. Regulatory bodies such as the FDA and EMA have established clear guidelines for the approval of DNA-based vaccines and their delivery systems, expediting the pathway for market entry. Additionally, strategic partnerships and funding from entities like the Coalition for Epidemic Preparedness Innovations (CEPI) and the Bill & Melinda Gates Foundation are supporting large-scale clinical trials and manufacturing infrastructure. These initiatives are particularly vital in emerging markets, where the need for affordable and scalable immunization solutions is paramount. As a result, the global landscape for DNA vaccine electroporation patches is rapidly evolving, with both established players and new entrants vying for market share through innovation, strategic alliances, and regional expansion.

From a regional perspective, North America currently dominates the DNA Vaccine Electroporation Patch market, accounting for the largest revenue share in 2024. This is primarily due to advanced healthcare infrastructure, high R&D spending, and the presence of leading biotechnology firms. Europe follows closely, benefiting from robust regulatory frameworks and an increasing focus on personalized medicine. Meanwhile, the Asia Pacific region is emerging as a high-growth market, driven by rising healthcare investments, expanding immunization programs, and the growing prevalence of infectious diseases. Latin America and the Middle East & Africa are also witnessing steady growth, supported by international aid, public health initiatives, and the gradual adoption of advanced medical technologies. This regional diversification is expected to create new opportunities for market participants and foster a competitive lands

Vaccines Transport Boxes Market Outlook

The global vaccines transport boxes market size was valued at approximately $1.2 billion in 2023 and is anticipated to expand to about $2.4 billion by 2032, registering a compound annual growth rate (CAGR) of 8.1% over the forecast period. This growth can be attributed to the increasing demand for efficient vaccine distribution systems, driven by the global vaccination initiatives and the rising complexity of vaccine cold chain logistics. The market is poised for substantial growth as governments and health organizations worldwide strive to enhance their vaccine supply chain infrastructures, ensuring safe and effective delivery of vaccines even to the remotest areas.

One of the primary growth factors for the vaccines transport boxes market is the unprecedented global vaccination efforts against diseases like COVID-19, which have underscored the need for robust cold chain solutions. The pandemic accelerated the demand for vaccines transport boxes as countries embarked on mass immunization campaigns, highlighting the critical role of these boxes in maintaining vaccine efficacy. Additionally, the emergence of new vaccines and booster doses for various infectious diseases necessitates a reliable and scalable transport solution, further fueling market growth. This trend is expected to continue as healthcare systems strengthen their immunization programs to prevent future pandemics and outbreaks.

Technological advancements in the design and functionality of vaccines transport boxes are also contributing significantly to market growth. Manufacturers are investing in research and development to introduce innovative products with enhanced insulation properties, temperature monitoring capabilities, and sustainable materials. These advancements not only improve the efficiency of vaccine transportation but also align with global sustainability goals, thereby appealing to environmentally conscious organizations. The introduction of smart transport boxes equipped with IoT technologies for real-time temperature tracking and data analytics is revolutionizing the market, offering improved reliability and efficiency in vaccine distribution.

Furthermore, the growing awareness about the importance of maintaining the cold chain in vaccine logistics is driving demand for vaccines transport boxes. Health organizations and governments are increasingly recognizing the critical role that transport boxes play in ensuring vaccine potency from the point of manufacture to administration. This awareness is strengthening regulations and standards concerning vaccine storage and transportation, compelling healthcare providers and logistics companies to invest in quality transport solutions. The heightened focus on vaccine cold chain integrity is expected to drive sustained demand for vaccines transport boxes over the forecast period.

In addition to the advancements in transport technology, the focus on Vaccines Packaging is becoming increasingly significant. Effective packaging solutions are essential to safeguard the integrity and potency of vaccines throughout the distribution process. With the rise of complex vaccine formulations, packaging must ensure protection against temperature fluctuations, physical damage, and contamination. Innovations in packaging materials, such as tamper-evident seals and multi-layered insulation, are enhancing the safety and reliability of vaccine delivery. As the demand for vaccines continues to grow, the role of specialized packaging in maintaining the cold chain and ensuring regulatory compliance is more crucial than ever.

From a regional perspective, the Asia Pacific vaccines transport boxes market is expected to witness significant growth during the forecast period. This growth can be attributed to the large population base, increasing government vaccination initiatives, and improving healthcare infrastructure in countries like China and India. In North America and Europe, the market is driven by the presence of advanced healthcare systems and established cold chain logistics networks. Meanwhile, Latin America and the Middle East & Africa are anticipated to experience moderate growth, supported by international aid and investments in healthcare improvements. These regions are focusing on expanding their capabilities to manage vaccine storage and distribution efficiently.

Product Type Analysis

The vaccines transport boxes market is segmented into three main product types: insulated boxes, refrige

Poisson model of individual- and zip code-level factors associated with receipt of primary COVID-19 vaccination series and booster.

BackgroundCanine transmitted rabies kills an estimated 59,000 people annually, despite proven methods for elimination through mass dog vaccination. Challenges in directing and monitoring numerous remote vaccination teams across large geographic areas remain a significant barrier to the up-scaling of focal vaccination programmes to sub-national and national level. Smartphone technology (mHealth) is increasingly being used to enhance the coordination and efficiency of public health initiatives in developing countries, however examples of successful scaling beyond pilot implementation are rare. This study describes a smartphone app and website platform, “Mission Rabies App”, used to co-ordinate rabies control activities at project sites in four continents to vaccinate over one million dogs.MethodsMission Rabies App made it possible to not only gather relevant campaign data from the field, but also to direct vaccination teams systematically in near real-time. The display of user-allocated boundaries on Google maps within data collection forms enabled a project manager to define each team’s region of work, assess their output and assign subsequent areas to progressively vaccinate across a geographic area. This ability to monitor work and react to a rapidly changing situation has the potential to improve efficiency and coverage achieved, compared to regular project management structures, as well as enhancing capacity for data review and analysis from remote areas. The ability to plot the location of every vaccine administered facilitated engagement with stakeholders through transparent reporting, and has the potential to motivate politicians to support such activities.ResultsSince the system launched in September 2014, over 1.5 million data entries have been made to record dog vaccinations, rabies education classes and field surveys in 16 countries. Use of the system has increased year-on-year with adoption for mass dog vaccination campaigns at the India state level in Goa and national level in Haiti.ConclusionsInnovative approaches to rapidly scale mass dog vaccination programmes in a sustained and systematic fashion are urgently needed to achieve the WHO, OIE and FAO goal to eliminate canine-transmitted human deaths by 2030. The Mission Rabies App is an mHealth innovation which greatly reduces the logistical and managerial barriers to implementing large scale rabies control activities. Free access to the platform aims to support pilot campaigns to better structure and report on proof-of-concept initiatives, clearly presenting outcomes and opportunities for expansion. The functionalities of the Mission Rabies App may also be beneficial to other infectious disease interventions.

The oral vaccine delivery market is poised for significant growth, driven by increasing demand for convenient and needle-free vaccination solutions. The market's expansion is fueled by several key factors. Firstly, the inherent ease of administration of oral vaccines, eliminating the need for trained medical personnel and specialized equipment, makes them particularly attractive in resource-limited settings and for mass vaccination campaigns. Secondly, improved stability and efficacy of oral vaccines are being achieved through ongoing research and development, overcoming previous limitations and expanding their applicability to a broader range of diseases. This technological advancement is further enhanced by increasing consumer preference for non-invasive medical procedures, leading to higher acceptance and uptake of oral vaccines. We project a considerable market expansion from approximately $5 billion in 2025 to over $8 billion by 2029, reflecting a robust compound annual growth rate (CAGR). While the market presents significant opportunities, challenges remain. The development of effective oral vaccines often faces hurdles in ensuring sufficient immune response, particularly for certain antigens, demanding extensive research and development investments. Regulatory approval processes for novel oral vaccine formulations also contribute to the market's complexities and timelines. Furthermore, ensuring the stability and efficacy of oral vaccines under varying storage conditions (particularly in developing nations) is critical for successful market penetration. Despite these challenges, the ongoing advancements in formulation technology and increasing demand for user-friendly vaccination methods suggest a continuously expanding market over the forecast period, with specific segments such as rotavirus and polio vaccines contributing significantly to overall growth.